Literature DB >> 8063783

Effects of inhibitors on anion exchangers in rabbit renal brush border membrane vesicles.

K R McConnell1, P S Aronson.   

Abstract

Cl-formate, Cl-oxalate, and SO4-CO3 exchange participate in Cl and organic anion transport across the brush border membrane of the rabbit proximal tubule. To determine the functional similarity of these transporters to each other and to band 3, we characterized, in isolated membrane vesicles, the inhibition of these transporters by compounds known to inhibit erythrocyte band 3. 4,4'-Dinitro-2,2'-disulfonic stilbene (DNDS), diphenylamine-2-carboxylate (DPC), flufenamate, and 4-aceto-4'-isothiocyano-2,2'-disulfonic stilbene (SITS) were effective inhibitors of Cl-oxalate and SO4-CO3 exchange, suggesting at least some common structural motifs between these exchangers and band 3. Cl-formate exchange was relatively insensitive to DNDS and DPC but sensitive to flufenamate (IC50 = 43 microM). Sensitivity to DNDS but not 4-amino-4'-amino-2,2'-disulfonic stilbene, a feature of band 3, was seen only for the SO4-CO3 exchanger. None of the exchangers had significant affinity for dipyridamole, furosemide, or probenecid. Finally, the presence of DPC or flufenamate increased the IC50 for reversible inhibition by DNDS, consistent with at least a partial overlap between the disulfonic stilbene and diphenylamine carboxylate binding sites of the Cl-oxalate exchanger. We next examined the effect of irreversible SITS binding. The Cl-oxalate exchanger was inhibited 90%, consistent with its high affinity for reversible inhibition by stilbenes. SITS pretreatment caused 50% inhibition of the Cl-formate exchanger, consistent with the reduced affinity of this exchanger for reversible binding of stilbenes. Despite the high sensitivity of the SO4-CO3 exchanger to reversible inhibition by stilbenes, SITS pretreatment caused < 20% irreversible inhibition of this exchanger. Finally, we characterized the stilbene inhibition of the Cl-oxalate exchanger in more detail. The presence of oxalate increased the IC50 for reversible inhibition by DNDS or SITS, implying that oxalate can directly compete at the reversible stilbene binding site of the Cl-oxalate exchanger. However, oxalate could not protect against covalent inactivation of the Cl-oxalate exchanger by SITS, indicating the presence of a separate site for irreversible binding of disulfonic stilbenes. These results suggest a dissociation between the sensitivities of proximal tubule anion exchangers to reversible and irreversible inhibition by disulfonic stilbenes. In contrast to band 3, the Cl-oxalate exchanger must possess separate sites for reversible and irreversible interaction with stilbenes, with only the former overlapping the substrate binding site.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063783

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells.

Authors:  F Knauf; C L Yang; R B Thomson; S A Mentone; G Giebisch; P S Aronson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-17       Impact factor: 11.205

Review 2.  Genes in idiopathic calcium oxalate stone disease.

Authors:  H O Goodman; R Brommage; D G Assimos; R P Holmes
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 3.  Oxalate transport and calcium oxalate renal stone disease.

Authors:  C F Verkoelen; J C Romijn
Journal:  Urol Res       Date:  1996

4.  Slc26a6: a cardiac chloride-hydroxyl exchanger and predominant chloride-bicarbonate exchanger of the mouse heart.

Authors:  Bernardo V Alvarez; Dawn M Kieller; Anita L Quon; Daniel Markovich; Joseph R Casey
Journal:  J Physiol       Date:  2004-10-21       Impact factor: 5.182

5.  Isothiocyanatostilbenes as novel c-Met inhibitors.

Authors:  Alana L Gray; David T Coleman; Reneau F Castore; Mohamed M Mohyeldin; Khalid A El Sayed; James A Cardelli
Journal:  Oncotarget       Date:  2015-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.